SecBot SecBot
SECBOTREPLAY Home › Report › CABA

CABA · Cabaletta Bio updated its corporate presentation with clinical data…

Cabaletta Bio, Inc. · 8-K filed Apr 20, 2026 at 07:01 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 20, 2026 at 07:01 ET

Cabaletta Bio updated its corporate presentation with clinical data showing positive safety and efficacy results from its autoimmune-focused CAR-T therapy rese-cel across multiple trials, including myositis, lupus, and myasthenia gravis, while advancing innovations in preconditioning elimination and automated manufacturing.

  • Posted updated corporate presentation with clinical data from RESET trials
  • Rese-cel demonstrated favorable safety profile with 95% of patients experiencing no or Grade 1 CRS
  • Positive efficacy data in multiple autoimmune conditions including myositis, SLE, and myasthenia gravis
  • Advancing innovations in preconditioning elimination and automated manufacturing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access